Transarterial chemoembolization (TACE) in the management of hepatocellular carcinoma: Results of a French national survey on current practices

Bruix, 2011, Management of hepatocellular carcinoma: an update, Hepatology, 53, 1020, 10.1002/hep.24199 2012, EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma, J Hepatol, 56, 908, 10.1016/j.jhep.2011.12.001 Delicque, 2016, Interventional oncology for hepatocellular carcinoma, Clin Res Hepatol Gastroenterol, 40, 530, 10.1016/j.clinre.2016.01.007 Kim, 2014, Transarterial chemoembolization vs. radiofrequency ablation for the treatment of single hepatocellular carcinoma 2cm or smaller, Am J Gastroenterol, 109, 1234, 10.1038/ajg.2014.152 Qi, 2015, Hepatic resection versus transarterial chemoembolization for the initial treatment of hepatocellular carcinoma: a systematic review and meta-analysis, Oncotarget, 6, 18715, 10.18632/oncotarget.4134 Hsu, 2012, Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function, Eur J Radiol, 81, 466, 10.1016/j.ejrad.2010.12.058 Xie, 2014, The efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization for primary hepatocellular carcinoma in a cohort of 487 patients, PLOS ONE, 9, e89081, 10.1371/journal.pone.0089081 Boulin, 2011, Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma, Anticancer Drugs, 22, 741, 10.1097/CAD.0b013e328346a0c5 Boulin, 2016, Which is the best chemotherapeutic agent for transarterial chemoembolization of hepatocellular carcinoma?, Cardiovasc Intervent Radiol, 39, 953, 10.1007/s00270-016-1319-0 Cammà, 2002, Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials, Radiology, 224, 47, 10.1148/radiol.2241011262 Llovet, 2003, Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival, Hepatology, 37, 429, 10.1053/jhep.2003.50047 Lencioni, 2016, Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data, Hepatology, 64, 106, 10.1002/hep.28453 Pelage, 2017, Chemoembolization of neuroendocrine liver metastases using streptozocin and tris-acryl microspheres: Embozar (EMBOsphere+ZAnosaR) study, Cardiovasc Intervent Radiol, 40, 394, 10.1007/s00270-016-1535-7 Lammer, 2010, Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study, Cardiovasc Intervent Radiol, 33, 41, 10.1007/s00270-009-9711-7 Basile, 2012, Quality-improvement guidelines for hepatic transarterial chemoembolization, Cardiovasc Intervent Radiol, 35, 765, 10.1007/s00270-012-0423-z Brown, 2009, Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy, J Vasc Interv Radiol, 20, S219, 10.1016/j.jvir.2009.04.033 Bargellini, 2014, Trends in utilization of transarterial treatments for hepatocellular carcinoma: results of a survey by the Italian Society of Interventional Radiology, Cardiovasc Intervent Radiol, 37, 438, 10.1007/s00270-013-0656-5 Tsetis, 2016, The provision of interventional radiology services in Europe: CIRSE recommendations, Cardiovasc Intervent Radiol, 39, 500, 10.1007/s00270-016-1299-0 Hocquelet, 2017, Transarterial chemoembolization for early stage hepatocellular carcinoma decrease local tumor control and overall survival compared to radiofrequency ablation, Oncotarget, 8, 32190, 10.18632/oncotarget.12921 Raoul, 2011, Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization, Cancer Treat Rev, 37, 212, 10.1016/j.ctrv.2010.07.006 Gorodetski, 2017, Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization, Eur Radiol, 27, 526, 10.1007/s00330-016-4445-9 Han, 2015, Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system, World J Gastroenterol, 21, 10327, 10.3748/wjg.v21.i36.10327 Colombo, 2015, Treatment of hepatocellular carcinoma: beyond international guidelines, Liver Int, 35, 129, 10.1111/liv.12713 Patel, 2006, Effectiveness of an aggressive antibiotic regimen for chemoembolization in patients with previous biliary intervention, J Vasc Interv Radiol, 17, 1931, 10.1097/01.RVI.0000244854.79604.C1 Khan, 2011, Moxifloxacin prophylaxis for chemoembolization or embolization in patients with previous biliary interventions: a pilot study, Am J Roentgenol, 197, W343, 10.2214/AJR.10.6019 Miyayama, 2009, Usefulness of cone-beam computed tomography during ultraselective transcatheter arterial chemoembolization for small hepatocellular carcinomas that cannot be demonstrated on angiography, Cardiovasc Intervent Radiol, 32, 255, 10.1007/s00270-008-9468-4 Yamakado, 2012, Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis?, Jpn J Radiol, 30, 560, 10.1007/s11604-012-0088-1 Lencioni, 2013, Chemoembolization of hepatocellular carcinoma, Semin Intervent Radiol, 30, 3, 10.1055/s-0033-1333648 de Baere, 2016, Treatment of liver tumors with Lipiodol TACE: technical recommendations from experts opinion, Cardiovasc Intervent Radiol, 39, 334, 10.1007/s00270-015-1208-y Matsui, 2017, Arteriopathy after transarterial chemo-lipiodolization for hepatocellular carcinoma, Diagn Interv Imaging, 98, 827, 10.1016/j.diii.2017.10.010 Varela, 2007, Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics, J Hepatol, 46, 474, 10.1016/j.jhep.2006.10.020 Guiu, 2012, Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads, J Hepatol, 56, 609, 10.1016/j.jhep.2011.09.012 Monier, 2017, Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion, Eur Radiol, 27, 1431, 10.1007/s00330-016-4488-y Boulin, 2015, Transarterial chemoembolization for hepatocellular carcinoma: an old method, now flavor of the day, Diagn Interv Imaging, 96, 607, 10.1016/j.diii.2015.04.005 Takaki, 2009, Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas larger than 5cm, J Vasc Interv Radiol, 20, 217, 10.1016/j.jvir.2008.10.019 Zheng, 2014, Transcatheter arterial chemoembolization combined with radiofrequency ablation can improve survival of patients with hepatocellular carcinoma with portal vein tumour thrombosis: extending the indication for ablation?, Clin Radiol, 69, e253, 10.1016/j.crad.2014.01.015 Vilgrain, 2017, Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial, Lancet Oncol, 18, 1624, 10.1016/S1470-2045(17)30683-6 Tavernier, 2014, Comparison of two transarterial chemoembolization strategies for hepatocellular carcinoma, Anticancer Res, 34, 7247 Prajapati, 2013, mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE), Ann Oncol, 24, 965, 10.1093/annonc/mds605 Paul, 2017, Evaluation of tumor response to intra-arterial chemoembolization of hepatocellular carcinoma: comparison of contrast-enhanced ultrasound with multiphase computed tomography, Diagn Interv Imaging, 98, 253, 10.1016/j.diii.2016.09.002